ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — H. C. Wainwright BioConnect Conference 2022

24 slides from ThermoGenesis's conference presentation, Jan 10, 2022

  1. Slide 1: ThermoGenesis Holdings, H. C. Wainwright BioConnect Conference

    ThermoGenesis Holdings, Inc. (NASDAQ:THMO) ThermoGenesis Holdings, Inc. | Jeff Cauble, CFO H. C. Wainwright BioConnect Conference (2022) 4 Thermocénsis outage ine:f Wasa ThermoGenesis¥

  2. Slide 2: Disclosure and Forward-Looking Statement

    a | Disclosure and Forward-Looking Statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s curren

  3. Slide 3: ThermoGenesis Holdings Company Highlights

    3 | ThermoGenesis Holdings, Inc. (Nasdaq: THMO) Headquarters mpany Highlights * History: Founded in 1986, headquartered in Rancho Cordova, CA. THMO is a leading medical device company to provide automated cellular processing devices for the cell banking and cell therapy industry. * Medical Device Pr

  4. Slide 4: ThermoGenesis Financial Snapshot

    ThermoGenesis Financial Snapshot Revenue (TTM) $10M Cash S8M Working Capital $11M Employees 50 Market Cap + $22M (rly atures) + Market Capas of 1/3/2022 ThermoGenesis Holdings, Inc. | NASDAQ:THMO ThermoGenesis

  5. Slide 5: Financial Review — Improved Balance Sheet

    Financial Review — Improved Balance Sheet Cash Working Capital (excluding convertible debt) $8.0 7.6M $12.0 $10.6m $10.0 pe $6.0 me 4.4M $8.0 a ATAM $4.0 2 $6.0 — $5.4 : 4.0 $2.0 ’ $2.0 $0.0 $0.0 9/30/18 9/30/20 9/30/22 g019 9/3720 ff21 * Cash up by 171% * Working Capital up by 96% ThermoGenesis Hol

  6. Slide 6: Full Product Lines for Automated Cellular Processing

    Full Product Lines for Automated Cellular Processing 1. CAR-TXpress™ Platform for Large Scale Cell Manufacturing 2. AXP® Platform and BioArchive Device for Stem Cell Banking 3. PXP® Platform for Point-of-Care Clinical Applications ThermoGenesis Holdings, Inc. | NASDAQ:THMO ThermoGenesis*

  7. Slide 7: AXP®: Leading Automated Technology for Cord Blood Banks

    7|| AXP®: Leading Automated Technology for Cord Blood Banks CO fetter cordlife .°¢. Kine mete ew Global Cord Blood Corporation @ TNYBC National Cord Blood Program ae enor AXP Processing Results: N=34,011 CBUs 7 ) ee ee) 5) ommsecenta |ratouenra| gee! 4 Snowe scoot] — tn on wala et ae ee waber| seins

  8. Slide 8: BioArchive®: Fully Automated Storage of Clinical Product

    | BioArchive®: Fully Automated Storage of Clinical Product ‘Sample in ovewrap bag pce in constr Individual storage, closed system, automated data tracking and built-in programmed freezing ThermoGenesis Holdings, Inc. | NASDAQ:THMO ThermoGenesis”

  9. Slide 9: X-Series® Products from our CAR-TXpress™ Platform

    | X-Series® Products from our CAR-TXpress™ Platform X-LAB Rapidly isolate mononuclear cells from various sources with this automated, functionally closed system. X-WASH Separate, wash, and reduce the volume of cells or cell cultures toa customized volume for tailored downstream applications. X-BACS

  10. Slide 10: Cell Isolation Technologies — FACS, MACS and BACS

    Low Capacity Fluorescence Activated Cell Sorting (FACS) since 1960s ThermoGenesis Holdings, Inc. | NASDAQ:THMO Medium Capacity — Magnetic Activated Cell Sorting (MACS) since 1990s | Cell Isolation Technologies — FACS, MACS and BACS® <> High Capacity Buoyancy Activated Cell Sorting (BACS*) since 2017

  11. Slide 11: Buoyancy Activated Cell Sorting (BACS) Technology

    sm @ Buoyancy Activated Cell Sorting (BACS) Technology Targetcells Non-Targetcells w/ beads w/o beads Traditional Technology: Magnetic Activated Cell Sorting (MACS) ThermoGenesis Holdings, Inc. | NASDAQ:THMO What It Is: * BACS uses microscopic bubbles (each smaller than a single cell) as cell isolat

  12. Slide 12: Manufacturing Cost & Capacity are Two Critical Unmet Needs

    sa § Manufacturing Cost & Capacity are Two Critical Unmet Needs Breakdown of cost of goods by component. Materials o 9 Currently, the drug costs for the two approved CAR-T cell therapies in the U.S. are $475,000 and $373,000 per dose, making them among the most expensive drugs in the market; manufac

  13. Slide 13: CAR-TXpress™ Platform — Improved Efficiency and Reduced Cost

    | CAR-TXpress™ Platform — Improved Efficiency and Reduced Cost ThermoGenesis' CAR-TXpress™ platform is a semi-automated, closed system for large-scale, high-efficiency cell manufacturing time while im of the manufacturing BioArchive® PXP®-BACS be the Vein-To-Vein appréach Bgdy — PXP®-Lavare sensor P

  14. Slide 14: Our Future: Enable High Efficiency Manufacturing for Cell Therapies

    14 | Our Future: Enable High Efficiency Manufacturing for Cell Therapies — Cell & gene therapies are advancing rapidly around the world, especially in CAR-T cell therapy field Worldwide Trials + 1,200+ Clinical Trials, + 900+ Companies Global Market * Global regenerative medicine ‘and cell therapy m

  15. Slide 15: Contract Development & Manufacturing Organization (CDMO) Transition

    Contract Development & Manufacturing Organization (CDMO) Transition 1. Significant shortage of capacity predicted in the CDMO industry in the coming years 2. Utilize the Company's cutting-edge technologies to provide cell manufacturing services. 3. BACS technology will provide a significant pricing

  16. Slide 16: Rationale to Transform into a Cell Therapy CDMO: Market Outlook

    acy @ Rationale to Transform into a Cell Therapy CDMO: Market Outlook To date, 5 CAR-T therapies have been approved. By 2025, US FDA expects 10-20 approvals/year for cell and gene therapy product. Over 65%+ of cell and gene therapies outsourced their manufacturing, however, only 5%-10% of required c

  17. Slide 17: Typical Cell Therapy CDMO Customer Profile

    17 Typical Cell Therapy CDMO Customer Profile Based on company size For Larger-Size Pharma Novartis, Gilead/Kite, Celgene/Juno — not have the manufacturing partners via CDMO or JV in overseas territorie For Medium & Small Size Co. ‘Small and medium size companies do ‘ource or capi in-house mfg. fac

  18. Slide 18: Cryoport — Share price up 2500%

    Cryoport (NASDAQ:CYRxX) — Share price up 2500% . I Revenue (2020) = $78M Current Market Cap $3.1 billion Manufacturer of Liquid Nitrogen Tanks [| a) 2 = iS ao) fal. a = ep) y i Transporting Life Shipping Logistic Solution Provider for Cell and Gene Therapy eo ThermoGenesis Holdings, Inc. | NASDAQ:TH

  19. Slide 19: BioLife — Share price up 2200%

    BioLife (NASDAQ:BLFS) — Share pies up 2200% Revenue (2020) = $48M Current Market Cap $2.3 billion Manufacturer of Culture & Freezing Media FL Supplements € “*BIOLIFE 7 SOLUTIONS cell and gene therapy tools mics z ThermoGenesis Holdings, Inc. | NASDAQ:THMO ThermoGenesi:

  20. Slide 20: MaxCyte — Share price up >1,000%

    MaxCyte (LON:MXCT) — Share price up >1,000% Maxcyte, ine (MACTL) somal @ Onsares © n [rics 1750 | — Bt] {sos (= Revenue (2020) = $22M | oO Current Market Cap $1.7B a | sooo o ieee a Electro-Transfection Device | = ) a 5 il ”n Y ik J a1ae0 CDMO Services faye >» me eo ThermoGenesis Holdings, Inc. | NA

  21. Slide 21: Peer Company Comparison

    yal § Peer Company Comparison From Scientific Tool Companies to Service & Solution Providers in Cell & Gene Therapy Field Company MaxCyte ThermoGenes! Ticker s : (NASDA (wv HMO) Business (Pre) trogen Tank Freezing Media & Buffer Electroporation Device _Cell Processing Device Business (Post) Cryo-shi

  22. Slide 22: THMO Update — Summary

    | THMO Update — Summary o A significant shortage of manufacturing capacity exist for cell & gene therapies. The high manufacturing cost and low manufacturing capability are key bottlenecks. o Current CDMO market is highly segmented, very few players having global access. o THMO targets to establish

  23. Slide 23: Experienced Leadership Team

    23 | Experienced Leadership Team Chris Xu, PhD, MBA, Chairman and Chief Executive Officer 20+ years in life sciences and pharmaceutical industry. Entrepreneur & investor, has invested in more than 20+ private and public companies. Invested close to $25 million into ThermoGenesis in the past three ye

  24. Slide 24: Pursuing Excellence for Cell Based Therapies

    Pursuing Excellence for Cell Based Therapies Cell Banking, Cell Process and Cell Therapy Company Contact: Investor Contact: For more information: ThermoGenesis Holdings, Inc. Rx Communications For ThermoGenesis, visit: Wendy Samford Paula Schwartz www.ThermoGenesis.com 916-858-5191 917-322-2216 ir@T

ThermoGenesis Holdings — H. C. Wainwright BioConnect Conference 2022 on 6ix